Resumo

FERNANDEZ DELGADO, Norma; FUNDORA SARRAFF, Teresa  e  MILANES ROLDAN, María Teresa. Thirty years of experience in the use of 32 phosphorus for Polycythemia Vera. Rev Cubana Hematol Inmunol Hemoter [online]. 2003, vol.19, n.2-3. ISSN 0864-0289.

A retrospective study of 279 patients suffering from Polycytemia Vera (PV) was made. Seventy-two of these patients (25%) were treated with 32 Phosphorus and followed-up for 4 to 28 years. The average age was 61 years on the first treatment. The hematological control was obtained in 95.8% of cases (n=69). The mean duration of the hematological control was 27.8 months. The total dose mean used per patient was 9.2±8.9 mCi. Thirty-four patients (54.1%) required the administration of more than one dose of the radioactive pharmaceutical during the evolution of the disease. Of all the treated patients, five (6.9%) developed acute leukemia 9 to 25 years after the first administration of the radiopharmaceutical and 3 (4.1%) developed other malignancies after 15 years of having been diagnosed or more. The post-treatment survival median was 10.1 years and the fundamental cause of death was vascular problems. 32 phosphorus treatment is undoubtedly a desirable effective therapeutical method for over 60 years-old patients since it assures excellent quality of life and extends the survival period, with minimum adverse reactions at a moderate cost

Palavras-chave : PHOSPHORUS [therapeutic use]; POLYCYTHEMIA VERA [radiotherapy]; QUALITY OF LIFE.